Company Profile
AbbVie Inc. Basic Information, Manufacturing Base, Sales Area, and Competitors
|
Sr. No. |
Item |
Description |
|
1 |
Company Name |
AbbVie Inc. |
|
2 |
Website |
www.abbvie.com |
|
3 |
Established Date |
2013 |
|
4 |
Headquartered |
United States |
|
5 |
Market Position/ History |
AbbVie Inc. is headquartered in North Chicago, Illinois, USA. The company was established in 2013 as a spin-off from Abbott Laboratories, focusing on specialty pharmaceuticals. AbbVie is ranked as one of the largest biomedical companies in the world, in 2023, it was listed at 74 on the Forbes Global 2000. |
|
6 |
Sales Area |
Worldwide |
|
7 |
Manufacturing Location |
United States |
|
8 |
No. of Employees |
Approximately 50,000 employees in over 70 countries as of January 31, 2024 |
|
9 |
Competitors |
|
|
10 |
CEO |
Richard A. Gonzalez |
|
11 |
Ownership Type |
Public |
|
12 |
Contact Information |
1 N. Waukegan Road North Chicago, Illinois 60064 Tel: 1-800-252-4415 |
Business Segment/ Overview:
AbbVie Inc. operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. AbbVie’s portfolio of products includes a broad line of therapies that address some of the world’s most complex and serious diseases.
Immunology products
AbbVie has an extensive portfolio in immunology, including rheumatology, dermatology, and gastroenterology. AbbVie's immunology products address the needs of patients with autoimmune diseases. These products include:
• Humira (adalimumab): AbbVie's leading product, with around $14 billion in revenue in 2023, is used to treat various autoimmune diseases.
• Skyrizi: An inhibitor of interleukin-23 (IL-23), which generated $7.8 billion in revenue in 2023, also targets autoimmune conditions.
• Botox: Known for aesthetic and therapeutic uses, contributing $5.7 billion in revenue in 2023.
• Other significant products include Imbruvica for cancer treatment, Rinvoq for arthritis, and Venclexta for leukemia and lymphoma.
Oncology products
AbbVie’s oncology products focus on some of the most challenging and difficult-to-treat cancers. These products are:
• Imbruvica. Imbruvica (ibrutinib) is an oral, once-daily therapy that inhibits a protein called Bruton’s tyrosine kinase.
• Venclexta/Venclyxto. Venclexta (venetoclax) is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
• Epkinly. Epkinly (epcoritimab) is used for adults with certain types of diffuse large
• B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has recurred or that does not respond to previous treatment after receiving two or more treatments.
• Others
Aesthetics products
AbbVie’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring and skincare products, which maintain leading positions in the U.S. and key markets globally. These products are:
• Botox Cosmetic. Botox Cosmetic is an inhibitor of acetylcholine release and a neuromuscular blocking agent used to temporarily improve the appearance of moderate to severe glabellar lines, crow’s feet, and forehead lines in adults.
• Others
Eye care products
AbbVie’s eye care products aim to fulfill unmet needs and pursue new approaches to help protect and preserve patients’ vision. These products include:
• Ozurdex: Ozurdex (dexamethasone intravitreal implant) is a corticosteroid implant that gradually releases medication over time. Injected directly into the back of the eye, it dissolves naturally and does not require removal.
• Lumigan/Ganfort: Lumigan (bimatoprost ophthalmic solution) 0.01% is a topical prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).
• Others
Micro Invasive Glaucoma Surgery MIGS Device Product Types Specification
|
Product |
Description |
|
XEN 45 GEL STENT |
The XEN45 Gel Stent is composed of a gelatin derived from porcine dermis, formed into a tube, and then cross-linked with glutaraldehyde. The durable gelatin is designed to minimally swell, soften, and become flexible when hydrated. The stent’s design also aids in retention of the XEN45 Gel Stent in its intended location after surgical implantation |
|
XEN Injector |
The XEN Injector is a single-use mechanical delivery system for the XEN 45 Gel Stent, which is preloaded in the XEN Injector for insertion and delivery into the eye. The XEN Injector allows the surgeon to advance and deliver the XEN 45 Gel Stent to the desired location. |
Recent Developments:
|
Year |
Latest News |
|
July 2022 |
AbbVie and iSTAR Medical Announced Strategic Alliance for the Treatment of Glaucoma AbbVie and iSTAR Medical SA, announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This complementary alliance will support iSTAR Medical's development and commercial efforts for MINIject, as well as provide an opportunity to expand AbbVie's eye care business, building on its glaucoma portfolio which includes drops, sustained release implants, and stent offerings. |
X
Profile Details
-
Author Anushka Gore
-
Published 23 Aug 2024
-
Last Updated 24 Aug 2024
-
Reading Time~5 minutes
-
CoverageSWOT, Financials, Key Employees, History
Table of Contents
-
- 1.1 About AbbVie Inc
- 1.2 Key Facts
- 1.3 Key Employees
- 1.3.1 Key Employee Biographies
- 1.4 History
- 1.5 Locations & Subsidiaries
- 1.5.1 Head Office
- 1.5.2 Other Locations & Subsidiaries
-
- 2.1 Company Overview
- 2.2 Business Segments
- 2.3 R&D Overview
- 2.4 Brands
- 2.5 Key Company Statistics
- 2.6 Key Financials (2015–2019)
- 2.7 Share Holder Analysis
- 2.8 Regional Presence
- 2.9 Services Offered
-
- 3.1 Strengths
- 3.2 Weaknesses
- 3.3 Opportunities
- 3.4 Threats
- 3.5 Key Competitors
-
- 4.1 Company Metrics
- 4.2 Key Investors
- 4.3 Recent Funding & Valuation
- 4.4 Historical Funding & Valuation
-
- 5.1 Acquisitions
- 5.2 Partnerships
-
- 6.1 Latest News & Announcements
- 6.2 Strategic Initiatives
-
- 7.1 Summary of Findings
- 7.2 Strategic Recommendations
Get a Custom Profile
Need a tailored company profile or competitive intelligence report? Our analysts are ready to help.
Contact Our ExpertsMore Profiles
Explore all published company profiles across 30+ industry verticals.
View All Profiles